Localized scleroderma (LS) is sclerosis of the skin characterized by one or multiple
circumscribed ivory-white, indurated, sometimes confluent plaques. It has been reported that …

Background Skin pigmentation disorders in systemic sclerosis (SSc) have been sparsely
described in the literature. Nevertheless, they could be a diagnostic and/or severity marker …

• Background and Design.—In a pilot study of extracorporeal photochemotherapy, two
patients with systemic sclerosis who received this therapy experienced significant clinical …

In this article we describe efficacy and safety aspects of ultraviolet A1 (UV-A1) phototherapy
in fibrosing conditions. UV-A1 is a specific phototherapeutic modality that is defined by a …

Systemic sclerosis is the rheumatic disease with the highest individual mortality. The severity
of the disease is determined by the extent of fibrotic changes to cutaneous and internal …

BACKGROUND: Increased collagen synthesis, vascular damage, and T-lymphocytic
infiltration contribute to the development of systemic sclerosis. Preliminary studies revealed …

The pathogenesis of systemic sclerosis (SSc) is complex, and the final story is yet to be
elucidated. The clinical heterogeneity of the disease, its various autoimmune and antibody …

Skin involvement is the hallmark and most clinically evident aspect of systemic sclerosis
(SSc). 1 Even the disease name is derived from skin involvement;“scleroderma” originates …

Background: Ultraviolet A (UVA) phototherapy proved to be an efficient line of treatment of
scleroderma. The mechanism through which it acts is still not clear. Objective: To detect the …

Purpose: To evaluate the efficacy of medium-dose UVA1 phototherapy in patients with
localized scleroderma. Method: A controlled pilot study with medium-dose UVA1 (48 J/cm2) …